Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NXTC Stock Forecast 2026-2027
$11.00
Current Price
$39.16M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NXTC Price Targets
+81.8%
To High Target of $20.00
+63.6%
To Median Target of $18.00
+36.4%
To Low Target of $15.00
NXTC Price Momentum
-5.5%
1 Week Change
-10.7%
1 Month Change
+154.0%
1 Year Change
-22.5%
Year-to-Date Change
-30.1%
From 52W High of $15.74
+195.7%
From 52W Low of $3.72
📊 TOP ANALYST CALLS
Did NXTC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NextCure is one of their latest high-conviction picks.
Latest NXTC Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, NXTC has a bullish consensus with a median price target of $18.00 (ranging from $15.00 to $20.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $11.00, the median forecast implies a 63.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Edward Tenthoff at Piper Sandler, suggesting a 36.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NXTC Analyst Ratings
3
Buy
0
Hold
0
Sell
NXTC Price Target Range
Low
$15.00
Average
$18.00
High
$20.00
Current: $11.00
Latest NXTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NXTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | Ladenburg Thalmann | Kevin DeGeeter | Buy | Upgrade | $18.00 |
| Jul 15, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $15.00 |
| Jul 1, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $3.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $3.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $3.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $4.00 |
| Aug 2, 2024 | Needham | Gil Blum | Buy | Reiterates | $4.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| May 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| May 3, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| May 3, 2024 | Needham | Gil Blum | Buy | Reiterates | $4.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $8.00 |
| Mar 20, 2024 | Needham | Gil Blum | Buy | Maintains | $4.00 |
| Dec 14, 2023 | Needham | Gil Blum | Buy | Maintains | $4.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $7.00 |
| Aug 4, 2023 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| May 5, 2023 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Mar 3, 2023 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Nov 4, 2022 | Needham | Gil Blum | Buy | Maintains | $6.00 |
| Nov 4, 2022 | Ladenburg Thalmann | Aydin Huseynov | Neutral | Downgrade | $N/A |
NextCure, Inc. (NXTC) Competitors
The following stocks are similar to NextCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NextCure, Inc. (NXTC) Financial Data
NextCure, Inc. has a market capitalization of $39.16M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -111.2%.
Valuation Metrics
Market Cap
$39.16M
Enterprise Value
$8.16M
P/E Ratio
-0.6x
PEG Ratio
-2.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+106.8%
Current Ratio
4.1x
Debt/Equity
14.7x
ROE
-111.2%
ROA
-55.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NextCure, Inc. (NXTC) Business Model
About NextCure, Inc.
What They Do
Develops innovative immunomedicines for cancer treatment.
Business Model
NextCure operates as a clinical-stage biopharmaceutical company, focusing on developing therapies for cancer patients who do not respond to existing treatments. The company generates revenue through the advancement of its drug pipeline, which includes proprietary therapies that target specific immune responses within the tumor microenvironment, potentially leading to profitable partnerships, licensing agreements, or product sales upon successful commercialization.
Additional Information
NextCure's proprietary FIND-IOTM technology is key to identifying novel immune targets, which could position the company favorably in the competitive oncology market. Their pipeline features advanced candidates like LNCB74, NC410, and NC525, which are designed to improve efficacy and reduce toxicity in cancer treatment. This focus on addressing significant unmet needs in oncology highlights the company's potential for growth and impact in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Mr. Michael S. Richman MSBA
Country
United States
IPO Year
2019
Website
www.nextcure.comNextCure, Inc. (NXTC) Latest News & Analysis
Latest News
Quick Summary
NextCure, Inc. (Nasdaq: NXTC) received FDA Fast Track Designation for SIM0505, an investigational ADC for platinum-resistant ovarian cancer, enhancing its development prospects.
Why It Matters
Fast Track Designation accelerates the development of SIM0505, potentially leading to quicker market entry and increased revenue opportunities for NextCure, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm focused on cancer therapies, has partnered with Simcere Zaiming Pharmaceutical Co., Ltd. for development efforts.
Why It Matters
NextCure's collaboration with Simcere Zaiming could enhance its drug development capabilities, potentially leading to breakthrough therapies, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NextCure, Inc. (Nasdaq: NXTC) released a business update and full-year 2025 financial results, focusing on developing novel cancer therapies.
Why It Matters
NextCure's business update and financial results could signal its progress in cancer therapy development, impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
NextCure Provides Business Update
2 months ago
Quick Summary
NextCure, Inc. (Nasdaq: NXTC) updated on its antibody drug conjugate programs and reported a preliminary cash position for year-end 2025, as of January 23, 2026.
Why It Matters
NextCure's ADC program updates and cash position are crucial indicators of its financial health and future growth potential in cancer therapies, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NextCure, Inc. (Nasdaq: NXTC) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3rd at 11:00 am ET, focusing on cancer therapies.
Why It Matters
NextCure's participation in a major healthcare conference signals potential investor interest and visibility, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
5 months ago
Quick Summary
NextCure, Inc. (Nasdaq: NXTC) has closed a PIPE, raising approximately $21.5 million, led by Ikarian Capital and other healthcare funds, to support its cancer therapy development.
Why It Matters
NextCure's successful $21.5 million PIPE indicates strong investor confidence, potentially enhancing its financial stability and funding for cancer therapies, impacting future growth and share performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NXTC Stock
What is NextCure, Inc.'s (NXTC) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, NextCure, Inc. (NXTC) has a median price target of $18.00. The highest price target is $20.00 and the lowest is $15.00.
Is NXTC stock a good investment in 2026?
According to current analyst ratings, NXTC has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NXTC stock?
Wall Street analysts predict NXTC stock could reach $18.00 in the next 12 months. This represents a 63.6% increase from the current price of $11.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NextCure, Inc.'s business model?
NextCure operates as a clinical-stage biopharmaceutical company, focusing on developing therapies for cancer patients who do not respond to existing treatments. The company generates revenue through the advancement of its drug pipeline, which includes proprietary therapies that target specific immune responses within the tumor microenvironment, potentially leading to profitable partnerships, licensing agreements, or product sales upon successful commercialization.
What is the highest forecasted price for NXTC NextCure, Inc.?
The highest price target for NXTC is $20.00 from at , which represents a 81.8% increase from the current price of $11.00.
What is the lowest forecasted price for NXTC NextCure, Inc.?
The lowest price target for NXTC is $15.00 from Edward Tenthoff at Piper Sandler, which represents a 36.4% increase from the current price of $11.00.
What is the overall NXTC consensus from analysts for NextCure, Inc.?
The overall analyst consensus for NXTC is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are NXTC stock price projections?
Stock price projections, including those for NextCure, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 9:30 AM UTC